Summary
- Milestone Pharmaceuticals aims to raise $86.25 million in a U.S. IPO.
- The firm is advancing programs to treat various cardiovascular conditions.
- MIST has shown promising Phase 2 trial results for its primary compound and has several related programs in earlier stages of development.
- I'll provide an update when we learn more details about the IPO.
- This idea was discussed in more depth with members of my private investing community, IPO Edge. Start your free trial today »
Quick Take
Milestone Pharmaceuticals (MIST) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing etripamil for the treatment of cardiovascular indications.
MIST has achieved promising Phase 2 trial results for its lead program. I’ll publish an update when we learn more details about the IPO.
